Vita Therapeutics, freshly infused with $32 million in financing, is advancing a novel approach to treating a localized form of muscular dystrophy with a cell therapy that combines a gene correction and induced pluripotent stem cell (iPSC) technology.
miRecule, Inc. (“miRecule”), an emerging biotech company focused on the development of cutting-edge RNA therapeutics, announced today it has closed over $5.7M in seed funding. The funding round was led by Alexandria Venture Investments, along with Boutique Venture Partners, Pathway Bioventures, Alumni Ventures Group, and national angel investors, with additional funding coming from the Maryland Momentum Fund and the FSHD Society. This funding includes a non-dilutive $2M Phase II SBIR grant from the National Cancer Institute.